Survival benefit after successful tricuspid valve transcatheter edge-to-edge repair in patients with high TRI-SCORE—insights from the EuroTR registry

Read full text Summarise with VIRAT
Authors: Matthias Gröger, Jörg Hausleiter, Dominik Felbel, Wolfgang Rottbauer, Karl‐Patrik Kresoja, Jennifer von Stein, Vera Fortmeier, Christoph Pauschinger, Mohammad Kassar, Bjoern Goebel, Paolo Denti, Paul Achouh
+41 more Tienush Rassaf, Manuel Barreiro‐Pérez, Peter Boekstegers, Andreas Rück, Monika Zdanytė, Marianna Adamo, Flavien Vincent, Philipp Schlegel, Sebastian Rosch, Mirjam Gauri Wild, Christian Besler, Stefan Toggweiler, Stephanie Brunner, Julia Grapsa, Tiffany Patterson, Hölger Thiele, Tobias Kister, Giuseppe Tarantini, Giulia Masiero, Marco De Carlo, Alessandro Sticchi, Fabian Voss, Amin Polzin, Antonio Popolo Rubbio, Francesco Bedogni, Mathias H. Konstandin, Eric VAN BELLE, Marco Metra, Tobias Geisler, Rodrigo Estévez‐Loureiro, Amir Abbas Mahabadi, Nicole Karam, Francesco Maisano, Philipp Lauten, Fabien Praz, Daniel Kalbacher, Volker Rudolph, Christos Iliadis, Philipp C. Lurz, Lukas Stolz, Mirjam Kessler
Cited by: 0
References: 9

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Tricuspid valve transcatheter edge-to-edge repair (T-TEER) is increasingly recognized as an effective treatment option for patients with tricuspid regurgitation (TR), improving symptoms and quality of life.1,2 With specific risk assessment tools lacking, TRI-SCORE, a surgically developed risk score, has been suggested for use in T-TEER patients.3 TRI-SCORE is based on eight dichotomous items and thus defines low, intermediate and high periprocedural risk.3 Recently, studies reported better survival after successful T-TEER only in patients with low or intermediate TRI-SCORE with no additional benefit in those with high score values.4,5 This present study aimed to assess the impact of procedural success of T-TEER on mortality of patients with low-to-moderate or high periprocedural risk according to TRI-SCORE in a large contemporary cohort. Patients from the multicentric European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR registry) were retrospectively included and grouped according to TRI-SCORE as previously published (3): low score (0–3), intermediate score (4–5) and high score (≥6). Only patients with a full TRI-SCORE dataset were included. Patients with low and intermediate TRI-SCORE were pooled and compared with high-score patients. A score of ≥9 defined an additional very-high-score category. TR at baseline and after the procedure was assessed using a five-grade system.6 Procedural success was defined as reduction of TR to less than moderate (grade ≤2+) at the time of discharge. The primary study endpoint was all-cause mortality through a 2-year follow-up period. Statistical analysis was performed using SPSS 29 software (IBM Corp., Armonk, USA). Categorical variables are expressed as counts and percentages. Continuous parameters are presented as the median with interquartile range (IQR). Comparisons of variables were carried out using Kruskal–Wallis test or Chi-Square test, as appropriate. Survival was analyzed using the Kaplan–Meier method and log-rank test. A Cox proportional hazards regression model was designed to identify independent association with all-cause mortality up to 2 years within the respective TRI-SCORE risk groups. Multivariate adjustment was made for procedural success, age, sex, and comorbidities (atrial fibrillation, coronary artery disease, chronic obstructive lung disease, history of cardiac surgery). Differences were considered statistically significant when P < .05. The study was ethically approved and received oversight by the institutional ethics committees (NCT06307262, central ethics approval number 22-0759). It complies with the principles outlined in the declaration of Helsinki. 1062 patients were included in this analysis. Median age was 80.0 years (IQR 75.0–83.0 years) and 47.2% of patients were female. 130 patients (12.2%) had a low TRI-SCORE (0–3), 309 (29.1%) were classified as intermediate (score 4–5) and 623 (58.7%) had a high score of 6 or higher. A very high TRI-SCORE of ≥9 was found in 152 patients (14.3%). TR was more severe in patients with high compared with low-to-moderate TRI-SCORE (TR grade ≥4+ in 55.3 vs. 48.6%, P & .032). Dose of diuretics was higher in high-score patients (median dose of furosemide or equivalent 40.0 mg (IQR 20.0–80.0) vs. 20.0 mg (IQR 10.0–30.0), P < .001) while use of RAAS inhibitors and SGLT2 inhibitors was more frequent in low-score patients (61.5 vs. 52.1% and 15.1 vs. 9.6%, P & .003 and .01, respectively). No other differences with regard to medication use were seen. Procedural success was achieved in 88.5% of low-score, 83.4% of intermediate-score and 76.2% of high-score patients (P & .001). Median number of implanted devices was 2.0 (IQR 1.0–2.0) with no significant difference between TRI-SCORE groups or procedural success groups. No intraprocedural deaths occurred and 7-day mortality was 0, 0.6, and 0.8% (P & .59). Median follow-up was 368.5 days (IQR 150.7–714.0 days). In the low- and intermediate-score group (TRI-SCORE

Fields of Study & Subjects

Cardiac Valve Diseases and Treatments Infective Endocarditis Diagnosis and Management Cardiac Arrhythmias and Treatments

Publication details

Journal / source
European Journal of Heart Failure
Volume
28
Issue
4
Pages
660–663
Publication date
23 March 2026
Language
EN